Envoy Medical Inc. (NASDAQ:COCH) on Wednesday said it has completed enrollment of its pivotal clinical trial for the investigational fully implanted Acclaim cochlear implant for hearing loss.
The company implanted the 56th and final patient.
Differentiated Ear Implant
The investigational Acclaim fully implanted cochlear implant leverages the natural ear, rather than an external microphone, to capture sound using Envoy Medical’s proprietary implanted piezoelectric sensor technology.
Unlike traditional cochlear implants, the Acclaim device does not require an externally worn component on or in the ear, representing a differentiated approach in the cochlear implant market.
Pivotal Trial Concludes Enrollment
Envoy Medical believes it is the first cochlear implant manufacturer to complete enrollment in a U.S. pivotal trial for a fully implanted cochlear implant, positioning the company at the forefront of this next generation of hearing technology.
“Completing enrollment of a pivotal clinical trial that is evaluating …
This post was originally published here
